Clinical Expression of Calcium Sensing Receptor Polymorphism (A986S) in Normocalcemic and Asymptomatic Hyperparathyroidism.
Normocalcemic and asymptomatic hyperparathyroidism diagnosis are becoming more common. However, their pathophysiology is incompletely known. The aim of the present study was to evaluate the clinical effect of calcium-sensing receptor polymorphism (A986S) in normocalcemic and asymtomatic HPT. Prospective study conducted with 61 consecutive normocalcemic and asymptomatic HPT patients was followed up during a minimum period of 1 year. Secondary causes of hyperparathyroidism were ruled out. Calcium and phosphorus metabolism parameters were evaluated in at least 2 determinations during follow-up to classify as normocalcemic or asymptomatic hyperparathyroidism. Bone mineral density and A986S polymorphism genotype were also analyzed. Thiry-eight patients (62.3%) had the genotype A986A, and 23 (36.7%) patients had A986S (20 patients, 32.8%) or S986S (3 patients, 4.9%). Age, sex, and genotype distributions were comparable in both normocalcemic and asymptomatic hyperparathyroidism. In normocalcemic patients, S allele genotype was associated to statistically significant higher level of intact PTH: 92.0 (SD 18.5) vs. 110.6 (SD 24.4) pg/ml, p<0.05; and remained significant after adjustment by multiple linear regression. In asymptomatic hyperparathyroidism, A986A genotype resulted in a statistically significant higher level of intact PTH, alkaline phosphatase and procollagen amino-terminal propeptide; but only serum calcium remained as an independent predictor of serum intact PTH levels after a multiple linear regression. Bone mineral densitometry between genotypes did not show statistically significant differences. A986S polymorphism of CaSR is an independent predictor of PTH level in normocalcemic hyperparathyroidism patients, but not in asymptomatic hyperparathyroidism. More studies are needed to evaluate the effect of other polymorphisms in normocalcemic and asymptomatic hyperparathyroidism.
Endocrinology and Nutrition Service, University Hospital of Valladolid, Centro de Investigación de Endocrinología y Nutrición-University of Valladolid, Valladolid, Spain.
G
G
Díaz-Soto
Endocrinology and Nutrition Service, University Hospital of Valladolid, Centro de Investigación de Endocrinología y Nutrición-University of Valladolid, Valladolid, Spain.
E
E
Romero
Internal Medicine Service, Centro de Investigación de Endocrinología y Nutrición, Hospital Universitario Rio Hortega, Valladolid, Spain.
J L P
JLP
Castrillón
Endocrinology and Nutrition Service, University Hospital of Valladolid, Centro de Investigación de Endocrinología y Nutrición-University of Valladolid, Valladolid, Spain.
O I
OI
Jauregui
Endocrinology and Nutrition Service, University Hospital of Valladolid, Centro de Investigación de Endocrinología y Nutrición-University of Valladolid, Valladolid, Spain.
D
D
de Luis Román
D000368:Aged; D015519:Bone Density; D003720:Densitometry; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D006961:Hyperparathyroidism / Q000235:genetics* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D044169:Receptors, Calcium-Sensing / Q000235:genetics*
D044169:Receptors, Calcium-Sensing